Letters sent to healthcare professionals in December 2017

Letters were sent about cladribine (Litak and Leustat), radium-223-dichloride (Xofigo▼), and ERWINASE.

• From: Medicines and Healthcare products Regulatory Agency
• Published: 9 January 2018

• Therapeutic area: Cancer, Haematology, Neurology and Urology and nephrology

In December 2017, the following letters were sent to relevant healthcare professionals:

• Cladribine (Litak and Leustat): risk of progressive multifocal leukoencephalopathy (PML)

• Radium-223-dichloride (Xofigo▼): increased risk of death and fractures in a randomised clinical trial with Xofigo used in combination with abiraterone acetate and prednisolone/prednisone

• Vials of ERWINASE from batch 183a, 184a and 185a* should be used with a 5-micron filter needle

Article citation: Drug Safety Update volume 11 issue 6; January 2018: 6.

Published 9 January 2018